Abstract
Herpes Simplex Virus (HSV)-2 Candidate Vaccine Virus Deleted in Glycoprotein D (ΔgD-2) Elicits High-Titer Immunoglobulin (Ig)G2 Antibodies With Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Activity, Protects Mice From Skin and Vaginal Challenge With Clinical Isolates of HSV-1 and HSV-2, and Prevents the Establishment of Latency
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
